Medication info

Samsung Sitagliptin Plus Tablet 50/1000 mg

Prescription medicationApproval withdrawn
Ingredient · strength
Sitagliptin Phosphate Hydrate›Strength being verifiedMetformin Hydrochloride›Strength being verified
Manufacturer / importer
Samsung Pharmaceutical Co., Ltd.
Appearance
Dark red oval film-coated tablet
Packaging
28 tablets/bottle, 30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 201604235 · Approved 2016.07.08

This product's status changed to Approval withdrawn on 2023.08.11. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily; the dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching patients previously treated with another oral hypoglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; caution and appropriate monitoring are required. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Samsung Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes mellitus

  • Difficulty in controlling blood sugar in patients with type 2 diabetes
View approved original text

This medication is used as an adjunct to diet and exercise to help control blood sugar in patients with type 2 diabetes. It may be used alone in patients who have not previously been treated with diabetes medications, and it can be prescribed as an alternative when blood sugar control is difficult with monotherapy of Metformin or Sitagliptin. Additionally, it can be used in combination with Metformin and sulfonylureas or thiazolidinediones when blood sugar control is insufficient. For patients who have difficulty controlling blood sugar with insulin and Metformin combination therapy, insulin can be administered along with this drug. It is used in various treatment situations to improve blood sugar control in type 2 diabetes.

Dosage and Administration

Adult dosage

The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily; the dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching patients previously treated with another oral hypoglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; caution and appropriate monitoring are required. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication is used for the treatment of diabetes and contains two active ingredients: Sitagliptin and Metformin. Firstly, Sitagliptin can cause severe allergic reactions in some patients, so if symptoms such as rash or difficulty breathing occur, use should be discontinued immediately. Additionally, acute pancreatitis may occur, so if severe abdominal pain or vomiting occurs, consulting a doctor is necessary. Metformin can rarely cause a serious metabolic disorder called lactic acidosis, which requires prompt treatment. Patients with poor kidney function, heart failure, severe infections, or dehydration should not use this medication. Before and after undergoing tests with iodinated contrast agents, medication should be temporarily discontinued due to the risk of kidney damage and lactic acidosis. It is safest for pregnant or breastfeeding women to avoid taking this medication. Furthermore, irregular meals, intense exercise, or interactions with other medications can increase the risk of hypoglycemia or lactic acidosis, so caution is advised. While taking this medication, regular blood and kidney function tests should be conducted, and monitoring vitamin B12 levels is also recommended. Symptoms such as diarrhea, nausea, headache, and cold-like symptoms may occur, so if symptoms are severe, consulting a doctor is advised. In particular, when taking this medication with other diabetes medications such as insulin or sulfonylureas, hypoglycemic symptoms may occur more frequently, so blood sugar should be closely monitored. In case of surgery, medication should be stopped 48 hours prior to the procedure and resumed only after confirming that kidney function is normal post-recovery. Finally, this drug can also be used for the elderly, but dose adjustment and periodic testing are necessary due to declining kidney function. If symptoms such as sudden muscle pain, skin rash, or difficulty breathing occur while taking this medication, notify healthcare professionals immediately.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • severe and disabling arthralgia
  • vesiculobullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • anorexia
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • gastrointestinal discomfort
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air from entering and kept at room temperature between 1°C and 30°C. This helps maintain the drug's effectiveness and ensures safe use.

Appearance and packaging

Appearance

Dark red oval film-coated tablet

Package unit

28 tablets/bottle, 30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.